Phase 2 Lupus Trial, Recruiting NCT06155604 Sponsor: The University of Hong Kong Condition: Lupus
Back to Lupus

Phase 2 Lupus Trial, Recruiting

NCT06155604
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been diagnosed with lupus nephritis (lupus affecting the kidneys), confirmed by a kidney biopsy, specifically classified as Class III, IV, or V
  • You have chronic kidney disease with a kidney function level (eGFR) between 15 and 60 mL/min
  • Your lupus is currently in a quiet/stable phase, meaning your overall lupus activity score is low and your kidneys are not currently showing signs of active lupus flare
  • You have been on a steady, unchanged dose of prednisolone (a steroid, 5–7.5 mg per day) for at least the past 3 months, either on its own or combined with a stable dose of either MMF (mycophenolate mofetil, up to 1.5 g/day) or AZA (azathioprine, up to 150 mg/day)

Who may not be able to join:

  • You have a kidney disease confirmed by biopsy that is caused by something other than lupus, or you have an inherited kidney condition
  • You have Type 1 diabetes
  • Your kidney disease is at the most advanced stage (Stage 5), or you are already on dialysis or another form of kidney replacement therapy
  • You get urinary tract infections (UTIs) often
  • You have a history of a serious condition called ketoacidosis (a dangerous build-up of acids in the blood)

⚠️ Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Desmond Yap, MD (HK), The University of Hong Kong

Phone: 85222554385

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Registry
ClinicalTrials.gov
Start date
4 January 2023
Est. completion
31 December 2026

Where this trial is recruiting

Hong Kong

Primary endpoints

eGFR reduction

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov